Cargando…

Apoptosis pathways and their therapeutic exploitation in pancreatic cancer

Resistance to apoptosis (programmed cell death) is a characteristic feature of human malignancies including pancreatic cancer, which is one of the leading causes of cancer deaths in the western world. Defects in this intrinsic cell death program can contribute to the multistep process of tumorigenes...

Descripción completa

Detalles Bibliográficos
Autor principal: Fulda, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496136/
https://www.ncbi.nlm.nih.gov/pubmed/19382915
http://dx.doi.org/10.1111/j.1582-4934.2009.00748.x
_version_ 1782380354180481024
author Fulda, Simone
author_facet Fulda, Simone
author_sort Fulda, Simone
collection PubMed
description Resistance to apoptosis (programmed cell death) is a characteristic feature of human malignancies including pancreatic cancer, which is one of the leading causes of cancer deaths in the western world. Defects in this intrinsic cell death program can contribute to the multistep process of tumorigenesis, because too little cell death can disturb tissue homeostasis. Further, blockade of apoptosis pathways can cause treatment failure, because intact apoptosis signalling cascades largely mediate therapy-induced cytotoxicity. The elucidation of apoptosis pathways in pancreatic carcinoma over the last decade has resulted in the identification of various molecular defects. How apoptosis pathways can be exploited for the treatment of pancreatic cancer will be discussed in this review.
format Online
Article
Text
id pubmed-4496136
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-44961362015-07-13 Apoptosis pathways and their therapeutic exploitation in pancreatic cancer Fulda, Simone J Cell Mol Med Reviews Resistance to apoptosis (programmed cell death) is a characteristic feature of human malignancies including pancreatic cancer, which is one of the leading causes of cancer deaths in the western world. Defects in this intrinsic cell death program can contribute to the multistep process of tumorigenesis, because too little cell death can disturb tissue homeostasis. Further, blockade of apoptosis pathways can cause treatment failure, because intact apoptosis signalling cascades largely mediate therapy-induced cytotoxicity. The elucidation of apoptosis pathways in pancreatic carcinoma over the last decade has resulted in the identification of various molecular defects. How apoptosis pathways can be exploited for the treatment of pancreatic cancer will be discussed in this review. John Wiley & Sons, Ltd 2009-07 2009-03-27 /pmc/articles/PMC4496136/ /pubmed/19382915 http://dx.doi.org/10.1111/j.1582-4934.2009.00748.x Text en © 2009 The Author Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
spellingShingle Reviews
Fulda, Simone
Apoptosis pathways and their therapeutic exploitation in pancreatic cancer
title Apoptosis pathways and their therapeutic exploitation in pancreatic cancer
title_full Apoptosis pathways and their therapeutic exploitation in pancreatic cancer
title_fullStr Apoptosis pathways and their therapeutic exploitation in pancreatic cancer
title_full_unstemmed Apoptosis pathways and their therapeutic exploitation in pancreatic cancer
title_short Apoptosis pathways and their therapeutic exploitation in pancreatic cancer
title_sort apoptosis pathways and their therapeutic exploitation in pancreatic cancer
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496136/
https://www.ncbi.nlm.nih.gov/pubmed/19382915
http://dx.doi.org/10.1111/j.1582-4934.2009.00748.x
work_keys_str_mv AT fuldasimone apoptosispathwaysandtheirtherapeuticexploitationinpancreaticcancer